×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EQ – equillium, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EQ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/26
02:06 pm
eq
Equillium (NASDAQ:EQ) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Equillium (NASDAQ:EQ) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/20
06:04 pm
eq
Equillium to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Equillium to Participate in Upcoming Investor Conferences [Yahoo! Finance]
11/20
04:35 pm
eq
Equillium to Participate in Upcoming Investor Conferences
Medium
Report
Equillium to Participate in Upcoming Investor Conferences
11/5
06:26 pm
eq
Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript [Seeking Alpha]
Low
Report
Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript [Seeking Alpha]
11/4
08:30 am
eq
Equillium to Participate in Upcoming Investor Conferences
Medium
Report
Equillium to Participate in Upcoming Investor Conferences
11/3
04:05 pm
eq
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/27
03:56 am
eq
Cipla's flagship respiratory initiative Breathefree broadens its footprint in the UAE
Low
Report
Cipla's flagship respiratory initiative Breathefree broadens its footprint in the UAE
10/22
08:00 am
eq
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
Medium
Report
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/9
05:52 pm
eq
Form 4 Equillium, Inc. For: Jan 07 Filed by: Connelly Stephen
Low
Report
Form 4 Equillium, Inc. For: Jan 07 Filed by: Connelly Stephen
1/9
05:42 pm
eq
Form 4 Equillium, Inc. For: Jan 07 Filed by: Zedelmayer Christine
Low
Report
Form 4 Equillium, Inc. For: Jan 07 Filed by: Zedelmayer Christine
1/9
05:39 pm
eq
Form 4 Equillium, Inc. For: Jan 07 Filed by: Steel Bruce D.
Low
Report
Form 4 Equillium, Inc. For: Jan 07 Filed by: Steel Bruce D.
1/9
05:37 pm
eq
Form 4 Equillium, Inc. For: Jan 07 Filed by: Tom Penny
Low
Report
Form 4 Equillium, Inc. For: Jan 07 Filed by: Tom Penny
1/8
12:23 pm
eq
Form 144 Equillium, Inc. Filed by: Tom Penny
Medium
Report
Form 144 Equillium, Inc. Filed by: Tom Penny
12/23
04:24 pm
eq
Form 4 Equillium, Inc. For: Dec 23 Filed by: Zedelmayer Christine
High
Report
Form 4 Equillium, Inc. For: Dec 23 Filed by: Zedelmayer Christine
12/23
04:18 pm
eq
Form 144 Equillium, Inc. Filed by: Zedelmayer Christine
High
Report
Form 144 Equillium, Inc. Filed by: Zedelmayer Christine
12/15
05:40 pm
eq
Form 4 Equillium, Inc. For: Dec 12 Filed by: Zedelmayer Christine
Medium
Report
Form 4 Equillium, Inc. For: Dec 12 Filed by: Zedelmayer Christine
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
33.1%
12/9 Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis 17.3%
11/13 Form S-3 Equillium, Inc. 13.4%
1/24 Biocon Ltd. ADR (BCNQY) CEO Siddharth Mittal on Q3 2020 Results - Earnings Call Transcript [Seeking Alpha] 8.7%
1/2 Form 3 Equillium, Inc. For: Jan 01 Filed by: Zedelmayer Christine 7.6%
8/12 Q2/2019 6/30/2019 EPS -0.350 ZacksConsensus -0.340 ActVsEst (0.010) - Miss 5.6%
12/12 Form 4 Equillium, Inc. For: Dec 10 Filed by: Connelly Stephen 5.3%
3/30 Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital 4.2%
11/7 Equillium to Present at Investor Conferences in November 2019 4.0%
8/15 Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 3.6%
12/9 Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis 17.3%
11/13 Form S-3 Equillium, Inc. 13.4%
1/24 Biocon Ltd. ADR (BCNQY) CEO Siddharth Mittal on Q3 2020 Results - Earnings Call Transcript [Seeking Alpha] 8.7%
1/2 Form 3 Equillium, Inc. For: Jan 01 Filed by: Zedelmayer Christine 7.6%
8/12 Q2/2019 6/30/2019 EPS -0.350 ZacksConsensus -0.340 ActVsEst (0.010) - Miss 5.6%
12/12 Form 4 Equillium, Inc. For: Dec 10 Filed by: Connelly Stephen 5.3%
3/30 Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital 4.2%
11/7 Equillium to Present at Investor Conferences in November 2019 4.0%
8/15 Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 3.6%
TOP News Decliners
12/31
Equillium (NYSE: EQ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
-19.3%
8/5 Form 4 Equillium, Inc. For: Aug 01 Filed by: Keyes Jason A -17.3%
12/23 Hedge Funds Are Dumping Equillium, Inc. (EQ) [Yahoo! Finance News] -12.4%
11/15 Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health -8.1%
12/10 MDB, GNW among premarket gainer [Seeking Alpha] -8.0%
11/12 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus N/A ActVsEst N/A - N/A -7.5%
2/27 Equillium Strengthens Leadership Team with Key Appointments -5.5%
9/17 Equillium to Host Business Update Call on October 1, 2019 -4.7%
1/29 Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR -4.4%
3/26 Q4/2019 12/31/2019 EPS -0.440 ZacksConsensus -0.400 ActVsEst (0.040) - Miss -4.4%
8/5 Form 4 Equillium, Inc. For: Aug 01 Filed by: Keyes Jason A -17.3%
12/23 Hedge Funds Are Dumping Equillium, Inc. (EQ) [Yahoo! Finance News] -12.4%
11/15 Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health -8.1%
12/10 MDB, GNW among premarket gainer [Seeking Alpha] -8.0%
11/12 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus N/A ActVsEst N/A - N/A -7.5%
2/27 Equillium Strengthens Leadership Team with Key Appointments -5.5%
9/17 Equillium to Host Business Update Call on October 1, 2019 -4.7%
1/29 Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR -4.4%
3/26 Q4/2019 12/31/2019 EPS -0.440 ZacksConsensus -0.400 ActVsEst (0.040) - Miss -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: